Expanding 바카라 게임 사이트’s anesthesia portfolio
[by Yu, Suin] Viatris 바카라 게임 사이트 announced on August 20 that it has entered into a strategic partnership with MSD 바카라 게임 사이트, under which it will serve as the exclusive domestic promoter and distributor of Bridion (sugammadex sodium), a therapeutic agent for recovery from general anesthesia.
Bridion, a general anesthesia recovery agent developed by the multinational pharmaceutical company MSD (Merck, USA), was approved by the Ministry of Food and Drug Safety in October 2012 and introduced to the 바카라 게임 사이트n market in February 2013. Over the past decade, Bridion has established a firm presence in clinical practice as a therapeutic option that enables rapid and reliable recovery from muscle relaxation.
Through this strategic partnership, Viatris 바카라 게임 사이트 aims to broaden its product portfolio in the 바카라 게임 사이트n anesthesia sector, increasing patient access to treatment options while reinforcing its market position by capitalizing on its solid sales and marketing expertise in the general hospital segment.
“We are pleased to incorporate Bridion, a general anesthesia recovery agent developed by MSD, a global leader in innovative anesthesia, into our portfolio. This agreement further consolidates our partnership while ensuring that patients in need can access Bridion in a rapidly evolving market,” expressed Bill Schuster, CEO of Viatris Korea. “As a company committed to empowering patients to live healthier lives at every stage, Viatris Korea will continue its efforts to deliver safer and more effective treatment options to both healthcare professionals and patients.”
“With the signing of an exclusive agreement for Bridion with Viatris Korea, a company distinguished by its expertise in chronic diseases, we expect that surgical professionals and patients in Korea will continue to benefit from Bridion,” stated Kim Albert, CEO of MSD Korea. “On the foundation of this trustworthy partnership, both companies are committed to ensuring the stable supply of Bridion. Our company will further pursue its mission of building a healthier future for Koreans by introducing innovative medicines and improving treatment accessibility.”